Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Multiple Myeloma 43Prostatic Neoplasms 41Carcinoma, Non-Small-Cell Lung 36Breast Neoplasms 34Lymphoma 28Leukemia, Myeloid, Acute 25Lymphoma, Non-Hodgkin 21Melanoma 18Colorectal Neoplasms 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Ovarian Neoplasms 15Lung Neoplasms 15Hodgkin Disease 15Hematologic Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Neoplasms 13Neoplasm Metastasis 13Myelodysplastic Syndromes 13Sarcoma 12Leukemia, Lymphocytic, Chronic, B-Cell 12Wilms Tumor 11Head and Neck Neoplasms 11Carcinoma, Renal Cell 11Burkitt Lymphoma 11Triple Negative Breast Neoplasms 10Pancreatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Leukemia 9Glioma 9Fallopian Tube Neoplasms 9

Interventions

Taxes 2Radiation 2Paclitaxel 2trastuzumab biosimilar HLX02 1cixutumumab 1Trastuzumab 1Radiotherapy 1PF-05280014 1Ontruzant 1Ogivri 1Carboplatin 1CT-P6 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Esophageal Neoplasms × 30 days × Clear all
NCT03132922 2026-06-04

MAGE-A4ᶜ¹º³²T for Multi-Tumor

USWM, LLC (dba US WorldMeds)

Phase 1 Active not recruiting
71 enrolled 20 charts
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT01196390 2026-06-02

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
203 enrolled 22 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT01142388 2026-05-29

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled 8 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡